X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding aims to support the company's ongoing development of GM-3009 (ibogaine), a Kappa opioid receptor agonist. It is evaluated in the Preclinical trials for the treatment of Opioid-Related Disorders.
Lead Product(s): Ibogaine
Therapeutic Area: Psychiatry/Psychology Product Name: GM-3009
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Gilgamesh Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding March 14, 2024
Details:
The funding helps BioCorRx to focus on the clinical development of BICX104 (naltrexone) a biodegradable, long-acting subcutaneous pellet in combination with Bupropion. It is currently evaluated in preclinical studies for methamphetamine use disorder.
Lead Product(s): Naltrexone,Bupropion Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BICX104
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: BioCorRx
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 28, 2024
Details:
The net proceeds will fund longer toxicology studies and drug manufacturing of SBP-9330, a small molecule that targets a receptor called metabotropic glutamate receptor 2 (mGlu2) to support planned Phase 2 studies for nicotine cessation.
Lead Product(s): SBP-9330
Therapeutic Area: Psychiatry/Psychology Product Name: SBP-9330
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Camino Pharma
Deal Size: $9.0 million Upfront Cash: Undisclosed
Deal Type: Funding February 06, 2024
Details:
The funding will support development of a subcutaneous formulation of its anti-fentanyl monoclonal antibody, CSX-1004 SQ, an investigational product that has successfully entered Phase 1 studies for the reversal of acute opioid over dose of fentanyl and carfentanil drugs.
Lead Product(s): CSX-1004
Therapeutic Area: Psychiatry/Psychology Product Name: CSX-1004
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Cessation Therapeutics
Deal Size: $14.8 million Upfront Cash: Undisclosed
Deal Type: Funding October 18, 2023
Details:
Funding will support the studies of Cebranopadol, the first and only full, dual NOP/MOP receptor agonist and has demonstrated reduced cocaine and heroin self-administration and drug-seeking behaviors, reinforcing its potential as an effective treatment for OUD.
Lead Product(s): Cebranopadol
Therapeutic Area: Psychiatry/Psychology Product Name: TRN-228
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Tris Pharma Inc
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 28, 2023
Details:
The funding will be used for the development of SiteOne's selective NaV1.8 inhibitor, STC-004, an investigational, non-opioid treatment for acute and chronic pain conditions.
Lead Product(s): STC-004
Therapeutic Area: Neurology Product Name: STC-004
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: SiteOne Therapeutics
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 18, 2023
Details:
The funding will be used to develop Omeros’ lead orally administered compound from its proprietary phosphodiesterase 7 (PDE7) program OMS527 for the treatment of cocaine use disorder (CUD).
Lead Product(s): OMS527
Therapeutic Area: Psychiatry/Psychology Product Name: OMS527
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Omeros
Deal Size: $6.6 million Upfront Cash: Undisclosed
Deal Type: Funding April 10, 2023
Details:
The agreement covers the clinical development program of STP7 (mavoglurant) to treat patients diagnosed with cocaine use disorder (CUD), including a Phase 3 study.
Lead Product(s): Mavoglurant
Therapeutic Area: Psychiatry/Psychology Product Name: STP7
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Stalicla
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 08, 2023
Details:
Funding from the grant will support the study of company’s lead compound, PPL-138, for the treatment of cocaine use disorder (CUD) and the cost of advancing PPL-138 through its remaining preclinical studies and through Phase 1 human clinical trials.
Lead Product(s): PPL-138
Therapeutic Area: Psychiatry/Psychology Product Name: PPL-138
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Phoenix Pharmalabs
Deal Size: $8.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 06, 2022
Details:
The grant is intended to support continued development of TNX-1300 as a treatment for life threatening cocaine intoxication. In 2021, more than 24,900 individuals in the U.S. died from drug overdose deaths involving cocaine.
Lead Product(s): TNX-1300
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-1300
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Tonix Pharmaceuticals Holding Corp
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
